Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Modulation of the QT interval duration in hypertension with antihypertensive treatment

J. Klimas, P. Kruzliak, SW. Rabkin,

. 2015 ; 38 (7) : 447-54. [pub] 20150319

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010437
E-zdroje Online Plný text

NLK ProQuest Central od 2015-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2009-01-01 do 2015-11-30
Health & Medicine (ProQuest) od 2015-01-01 do Před 1 rokem

The duration of the QT interval as measured by 12-lead electrocardiography is a measure of myocardial repolarization and is widely used to describe cardiac abnormalities, to determine the presence of cardiac toxicity and to evaluate drug safety. In hypertension, the QT interval is a predictor of the risk of both coronary events and cardiovascular death, after adjusting for the effects of additional risk factors. The mechanism of QT interval prolongation is multifactorial and includes cardiomyocyte hypertrophy and increased left ventricular mass, with accompanying changes in left ventricular transmural dispersion of repolarization, as well as changes in the tone of the autonomic nervous system of some patients with hypertension and mechano-electrical feedback, although this mechanism is less likely. Antihypertensive drugs vary in their effect on QT interval duration. The mechanisms underlying their effect depend on changes in left ventricular mass and autonomic nervous system tone, as well as changes in the activity of cardiac ion channels. Although blood pressure reduction is the primary goal of antihypertensive drug therapy and although the choice of antihypertensive drug treatment regimens varies among different individuals, the data regarding the disparate effects of antihypertensive drugs on the duration of the QT interval warrant consideration when implementing long-term pharmacotherapy for hypertension.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010437
003      
CZ-PrNML
005      
20160414103242.0
007      
ta
008      
160408s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/hr.2015.30 $2 doi
024    7_
$a 10.1038/hr.2015.30 $2 doi
035    __
$a (PubMed)25787045
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Klimas, Jan $u Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic.
245    10
$a Modulation of the QT interval duration in hypertension with antihypertensive treatment / $c J. Klimas, P. Kruzliak, SW. Rabkin,
520    9_
$a The duration of the QT interval as measured by 12-lead electrocardiography is a measure of myocardial repolarization and is widely used to describe cardiac abnormalities, to determine the presence of cardiac toxicity and to evaluate drug safety. In hypertension, the QT interval is a predictor of the risk of both coronary events and cardiovascular death, after adjusting for the effects of additional risk factors. The mechanism of QT interval prolongation is multifactorial and includes cardiomyocyte hypertrophy and increased left ventricular mass, with accompanying changes in left ventricular transmural dispersion of repolarization, as well as changes in the tone of the autonomic nervous system of some patients with hypertension and mechano-electrical feedback, although this mechanism is less likely. Antihypertensive drugs vary in their effect on QT interval duration. The mechanisms underlying their effect depend on changes in left ventricular mass and autonomic nervous system tone, as well as changes in the activity of cardiac ion channels. Although blood pressure reduction is the primary goal of antihypertensive drug therapy and although the choice of antihypertensive drug treatment regimens varies among different individuals, the data regarding the disparate effects of antihypertensive drugs on the duration of the QT interval warrant consideration when implementing long-term pharmacotherapy for hypertension.
650    _2
$a zvířata $7 D000818
650    _2
$a antihypertenziva $x terapeutické užití $7 D000959
650    _2
$a elektrokardiografie $x účinky léků $7 D004562
650    _2
$a srdeční frekvence $x účinky léků $7 D006339
650    _2
$a lidé $7 D006801
650    _2
$a hypertenze $x diagnóza $x farmakoterapie $x patofyziologie $7 D006973
650    _2
$a hypertrofie levé komory srdeční $x farmakoterapie $x patofyziologie $7 D017379
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Kruzliak, Peter $u Department of Cardiovascular Diseases, International Clinical Research Centre, St Anne's University Hospital and Masaryk University, Brno, Czech Republic.
700    1_
$a Rabkin, Simon W $u Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
773    0_
$w MED00006041 $t Hypertension research official journal of the Japanese Society of Hypertension $x 1348-4214 $g Roč. 38, č. 7 (2015), s. 447-54
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25787045 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20160414103326 $b ABA008
999    __
$a ok $b bmc $g 1113866 $s 934805
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 38 $c 7 $d 447-54 $e 20150319 $i 1348-4214 $m Hypertension research $n Hypertens Res $x MED00006041
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...